Literature DB >> 34006960

Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.

Jaya Singh Kshatri1, Debdutta Bhattacharya1, Srikanta Kanungo1, Sidhartha Giri1, Subrata Kumar Palo1, Debaprasad Parai1, Jyotirmayee Turuk1, Asit Mansingh1, Hari Ram Choudhary1, Matrujyoti Pattnaik1, Girish Chandra Dash1, Prasantajyoti Mohanty1, Niranjan Mishra2, Durga Madhab Satapathy3, Sanjaya Kumar Sahoo3, Sanghamitra Pati4.   

Abstract

This was a population based cross-sectional study carried out to estimate and compare the seroprevalence, hidden prevalence and determine the demographic risk factors associated with SARS-CoV-2 infection among adults in the three largest cities of Odisha, India, and ascertain the association with the progression of the epidemic. The survey carried out in August 2020 in the three largest cities of the state of Odisha, India. Blood samples were collected from the residents using random sampling methods and tested for anti- SARS CoV-2 antibodies using an automated CLIA platform. A total of 4146 participants from the 3 cities of Bhubaneswar (BBS), Berhampur (BAM) and Rourkela (RKL) participated. The female to male participation ratio was 5.9:10 across the three cities. The gender weighted seroprevalence across the three cities was 20.78% (95% CI 19.56-22.05%). While females reported a higher seroprevalence (22.8%) as compared to males (18.8%), there was no significant difference in seroprevalence across age groups. A majority of the seropositive participants were asymptomatic (90.49%). The case to infection ratio on the date of serosurvey was 1:6.6 in BBS, 1:61 in BAM and 1:29.8 in RKL. The study found a high seroprevalence against COVID-19 in urban Odisha as well as high numbers of asymptomatic infections. The epidemic curves had a correlation with the seroprevalence.

Entities:  

Year:  2021        PMID: 34006960     DOI: 10.1038/s41598-021-89877-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  1 in total

1.  Evidence-based Guideline for Therapeutic Drug Monitoring of Vancomycin: 2020 Update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society.

Authors:  Na He; Shan Su; Zhikang Ye; Guanhua Du; Bei He; Dakui Li; Youning Liu; Kehu Yang; Xianglin Zhang; Yingyuan Zhang; Xiao Chen; Yaolong Chen; Zhigang Chen; Yalin Dong; Guang Du; Jian Gu; Daihong Guo; Ruichen Guo; Xin Hu; Zheng Jiao; Huande Li; Gaolin Liu; Zhiping Li; Yuan Lv; Wei Lu; Liyan Miao; Jieming Qu; Tieying Sun; Rongsheng Tong; Li Wang; Minggui Wang; Rui Wang; Aidong Wen; Jiuhong Wu; Xin'an Wu; Yingchun Xu; Yong Yang; Fan Yang; Siyan Zhan; Bikui Zhang; Chao Zhang; Huizhi Zhang; Jie Zhang; Jing Zhang; Jun Zhang; Wenting Zhang; Libo Zhao; Limei Zhao; Rongsheng Zhao; Wei Zhao; Zhigang Zhao; Wei Zhou; Xian-Tao Zeng; Suodi Zhai
Journal:  Clin Infect Dis       Date:  2020-12-23       Impact factor: 9.079

  1 in total
  5 in total

1.  Predictors for adult COVID-19 hospitalized inpatient mortality rate in North West Ethiopia.

Authors:  Fassikaw Kebede; Tsehay Kebede; Tilahun Gizaw
Journal:  SAGE Open Med       Date:  2022-03-04

2.  Investigating immunological interaction between lymphatic filariasis and COVID-19 infection: a preliminary evidence.

Authors:  Abhinav Sinha; Sanghamitra Pati; Prakash Kumar Sahoo
Journal:  Hum Vaccin Immunother       Date:  2021-10-29       Impact factor: 3.452

3.  Community seroprevalence and risk factors for SARS-CoV-2 infection in different subpopulations in Vellore, India, and their implications for future prevention.

Authors:  Divya Dayanand; Indhuja Irudhayanathan; Debasree Kundu; Abi Manesh; Vinod Abraham; Kundavaram Pp Abhilash; Binila Chacko; Mahesh Moorthy; Prasanna Samuel; Pimnara Peerawaranun; Mavuto Mukaka; Jayaraj Joseph; Mohanasankar Sivaprakasam; George M Varghese
Journal:  Int J Infect Dis       Date:  2021-12-28       Impact factor: 12.074

4.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ) IgG-antibody seroprevalence among quarantined population, during the first wave of COVID-19 pandemic, In North West Ethiopia (from 30 April to 30 May 2020).

Authors:  Fassikaw Kebede; Tsehay Kebede; Birhanu Kebede
Journal:  SAGE Open Med       Date:  2022-02-07

5.  Infection, cases due to SARS-CoV-2 in rural areas during early COVID-19 vaccination: findings from serosurvey study in a rural cohort of eastern India.

Authors:  Pujarini Dash; Asit Mansingh; Soumya Ranjan Nayak; Debadutta Sahoo; Debdutta Bhattacharya; Srikanta Kanungo; Jaya Singh Kshatri; Bijaya Kumar Mishra; Matrujyoti Pattnaik; Debaprasad Parai; Hari Ram Choudhary; Swetalina Nayak; Khokan Rana; Alice Alice; Ajay Kumar Sahoo; Kanhu Charan Mohanty; Prasantajyoti Mohanty; Chinki Doley; Hitesh Jain; Dasharatha Majhi; Pooja Pattanayak; Santosh Behuria; Soumya Panda; Somnath Bhoi; Sanghamitra Pati; Subrata Kumar Palo
Journal:  Epidemiol Infect       Date:  2022-03-03       Impact factor: 2.451

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.